When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
ALPMF - Xtandi extends survival in late-stage prostate cancer study
Astellas Pharma Inc
Astellas Pharma (OTCPK:ALPMF) and collaboration partner Pfizer (NYSE:PFE) announce final overall survival (OS) data from a Phase 3 clinical trial, PROSPER, evaluating Xtandi (enzalutamide) plus androgen deprivation therapy (ADT) in men with non-metastatic castration-resistant prostate cancer.
More news on: Astellas Pharma Inc., Pfizer Inc., Astellas Pharma Inc., Healthcare stocks news,